Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2014 2
2017 1
2019 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

5 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Determinants of antipsychotic response in schizophrenia: implications for practice and future clinical trials.
Rabinowitz J, Werbeloff N, Caers I, Mandel FS, Stauffer V, Ménard F, Kinon BJ, Kapur S. Rabinowitz J, et al. J Clin Psychiatry. 2014 Apr;75(4):e308-16. doi: 10.4088/JCP.13m08853. J Clin Psychiatry. 2014. PMID: 24813414
BACKGROUND: Response to antipsychotics in schizophrenia is highly variable, and determinants are not well understood or used to design clinical trials. OBJECTIVE: We aimed to understand determinants of response to antipsy
BACKGROUND: Response to antipsychotics in schizophrenia is highly variable, and determinants are not well unders …
Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness.
Barnes TR, Leeson VC, Paton C, Marston L, Davies L, Whittaker W, Osborn D, Kumar R, Keown P, Zafar R, Iqbal K, Singh V, Fridrich P, Fitzgerald Z, Bagalkote H, Haddad PM, Husni M, Amos T. Barnes TR, et al. Health Technol Assess. 2017 Sep;21(49):1-56. doi: 10.3310/hta21490. Health Technol Assess. 2017. PMID: 28869006 Free PMC article. Clinical Trial.
BACKGROUND: When treatment-refractory schizophrenia shows an insufficient response to a trial of clozapine, clinicians commonly add a second antipsychotic, despite the lack of robust evidence to justify this practice. ...The size and extent of the side …
BACKGROUND: When treatment-refractory schizophrenia shows an insufficient response to a trial of clozapine, clinicians commonl …
Evaluation of Prescribing Patterns of Long-Acting Injectable Antipsychotics Within a Community Health System.
Netley J, Gaul J, Ferguson C. Netley J, et al. J Clin Psychopharmacol. 2019 Sep/Oct;39(5):494-498. doi: 10.1097/JCP.0000000000001095. J Clin Psychopharmacol. 2019. PMID: 31425464
IMPLICATIONS/CONCLUSIONS: Inconsistencies were observed between labeling information and clinical practice for LAIAs prescribed within the community health system. ...This analysis may be hypothesis generating for future studies on LAIAs....
IMPLICATIONS/CONCLUSIONS: Inconsistencies were observed between labeling information and clinical practice for LAIAs pr
How antipsychotics impact the different dimensions of Schizophrenia: a test of competing hypotheses.
Marques TR, Levine SZ, Reichenberg A, Kahn R, Derks EM, Fleischhacker WW, Rabinowitz J, Kapur S. Marques TR, et al. Eur Neuropsychopharmacol. 2014 Aug;24(8):1279-88. doi: 10.1016/j.euroneuro.2014.04.001. Epub 2014 Apr 24. Eur Neuropsychopharmacol. 2014. PMID: 24862257
Using Structural Equation Modeling in two large [1884 patients] clinical trials in schizophrenia, we compared the model of a common general effect of antipsychotics to models whereby the antipsychotics have multiple and differential effects on t …
Using Structural Equation Modeling in two large [1884 patients] clinical trials in schizophrenia, we compared the model …
Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia.
Uchida H, Mamo DC, Kapur S, Labelle A, Shammi C, Mannaert EJ, Mann SW, Remington G. Uchida H, et al. J Clin Psychiatry. 2008 Aug;69(8):1281-6. doi: 10.4088/jcp.v69n0811. J Clin Psychiatry. 2008. PMID: 18642974 Clinical Trial.
OBJECTIVE: Long-acting risperidone administered intramuscularly biweekly is approved for the management of schizophrenia. However, dosing of long-acting antipsychotics is frequently extended in clinical practice, and a recent clinical trial has …
OBJECTIVE: Long-acting risperidone administered intramuscularly biweekly is approved for the management of schizophrenia. However, do …